Objective: During the menopausal transition and early postmenopause, participants in the Seattle Midlife Women's Health Study were likely to belong to one of three symptom severity classes: severe hot flashes with moderate sleep, mood, cognitive, and pain symptoms (high-severity hot flash); moderate levels of all but hot flashes (moderate severity); and low levels of all (low severity). We tested models of the differential effects of hypothalamic-pituitary-ovarian (HPO) axis, hypothalamic-pituitary-adrenal (HPA) axis, and autonomic nervous system (ANS) biomarkers on the three symptom severity classes.
A majority of women experiencing the menopausal transition (MT) and early postmenopause (PM) report being bothered by hot flashes 1<3 and co-occurring symptoms (symptom clusters). 4<7 Cray et al 8 identified three symptom severity clusters (latent classes) that the Seattle Midlife Women's Health Study (SMWHS) participants experienced and that were differentially associated with the stages of reproductive aging. The most prevalent cluster included low-severity hot flashes and mood, sleep, cognitive, and pain symptoms, accounting for approximately 70% of observations. Another cluster, accounting for approximately 13% of observations, was characterized by high-severity hot flashes and moderate-severity mood, sleep, cognitive, and pain symptoms, and was associated with the late MT and early PM. The third cluster, accounting for 17% of observations, included lowseverity hot flashes and moderate-severity sleep, mood, cognitive, and pain symptoms. 8 Several reports from longitudinal studies of the MT and early PM support the association between hypothalamicpituitary-ovarian (HPO) axis functioning and individual symptoms that women experience during this period. Recently published results from the Penn Ovarian Aging and the Study of Women's Health Across the Nation (SWAN) indicated that hot flashes were associated with estradiol and folliclestimulating hormone (FSH) levels and their variability. 4, 9 Studies of sleep symptoms during the MT and PM revealed that lower estradiol levels were associated with nighttime awakening, 10 and findings from the SWAN indicated that lower estradiol and higher FSH levels were associated with difficulty falling asleep and remaining asleep. 11 Moreover, these findings were supported by later studies of polysomnographic sleep in a subset of the SWAN participants. 12 In contrast, findings from the Penn Ovarian Aging cohort indicated that poor sleep was unrelated to estradiol, testosterone, and FSH. 13 Studies of depressed mood symptoms revealed mixed findings: depressed mood, as measured by the Center for Epidemiologic Studies Depression scale, was significantly associated with higher testosterone levels among the SWAN participants. 14 Among the Penn Ovarian Aging participants, depressed mood was associated with increased levels of FSH and leuteinizing hormone and increased variability in estradiol, FSH, and leuteinizing hormone. 15 Among the SMWHS participants, urinary estrone, FSH, and testosterone levels were not associated with scores on the Center for Epidemiologic Studies Depression scale, 16 consistent with the finding of no association between major depressive disorder and endocrine levels and change among the SWAN participants. 17 Cognitive symptoms were unrelated to HPO axis hormone levels in the SWAN, 18, 19 the SMWHS, 20 and the Penn Ovarian Aging. 21 Pain symptoms (aches, joint pain, and stiffness) have been associated with estrogen levels and variability in the Penn Ovarian Aging population. Aches, joint pain, and stiffness were associated with estradiol variability, 4 but neither joint pain nor back pain was associated with urinary levels of estrone or FSH in the SMWHS population. 22 To date, there has been little investigation of the role of the neuroendocrine effects associated with the hypothalamicpituitary-adrenal (HPA) axis and the autonomic nervous system (ANS) in the symptoms experienced by women during the MT and early PM. A rise in cortisol during the late MT stage was found in the SMWHS population, 23 but no difference in cortisol levels during the MT stages and early PM in the SWAN population has been reported. 24 In the SMWHS population, cortisol was positively associated with urinary estrone, epinephrine, and norepinephrine levels during the MT stages. 25 Early studies of hot flashes in laboratory settings involved inducing hot flashes and measuring endocrine responses. Meldrum et al 26 found that adrenocorticotropic hormone levels rose shortly after women experienced hot flashes, and that cortisol levels rose about 15 minutes after women experienced hot flashes. Moreover, Freedman 27 demonstrated associations between hot flashes and brain metabolites of norepinephrine (3-methoxy-4-hydroxyphenylglycol), but not peripheral metabolites of norepinephrine (vanillylmandelic acid), suggesting a role for brain levels of norepinephrine and hot flashes. In the SMWHS population, higher cortisol levels were associated with less severe problems getting to sleep, but not nighttime awakening or early morning awakening; epinephrine and norepinephrine levels were not associated with sleep symptoms. 10 Higher cortisol levels were associated with less back pain, and higher norepinephrine and epinephrine levels were marginally associated with higher levels of joint pain. 22 Depressed mood was not associated with cortisol, epinephrine, or norepinephrine levels, 16 nor were the cognitive symptoms difficulty concentrating and forgetfulness. 20 The modulation of HPO axis function by the HPA axis has been demonstrated in earlier work. 28 Although it is probable during the MT and early PM that changes in HPA axis and autonomic functioning will occur when ovarian function is transitioning to a new pattern in which estrogens are increasingly of nonovarian origin, to date, there have been no investigations of HPO axis, HPA axis, and autonomic influences on symptom report during this period, aside from hot flashes.
Data from the SMWHS support women's experience of multiple co-occurring symptoms and their relationship to the MT stages 8 ; however, to date, researchers have not explored the association between HPO axis, HPA axis, and ANS functions and symptom severity clusters. The primary approach to understanding the relationship between menopause and symptoms has been motivated by the hypothesis that changes in the HPO axis, such as declining estrogen and rising FSH levels, are responsible for individual symptoms. Identifying symptom severity clusters and related neuroendocrine mechanisms may serve as the basis for tailoring therapy to co-occurring symptoms characterized by the severity levels experienced by individual women and for suggesting novel approaches to symptom management for women during the MT and early PM. Therefore, the purpose of this study was to test a model hypothesizing the differential effects of HPO axis (urinary estrone, FSH, and testosterone), HPA axis (cortisol), and ANS (epinephrine and norepinephrine) biomarkers on symptom severity clusters that women experience during the MT and early PM.
METHODS

Sample and design
The current analysis used data from the longitudinal SMWHS, which included participants for as many as 20 years of follow-up. In the original study, 508 women were enrolled between 1990 and 1992. After completing an initial in-person interview, 390 women consented to provide data annually by questionnaire, daily menstrual calendar, and/or health diary. At the end of 5 years, 243 women consented to continue to participate for an additional 5 years, and 170 women agreed to provide a firstmorning urine specimen 8 to 12 times per year on day 6 of the menstrual cycle. 16, 29, 30 For the current analysis, the data set contained data from 292 women whose menstrual calendars could be assigned an MT stage and who provided diary data on at least one occasion. Participants (n = 130 of 292; 45%) eligible for this analysis were those who contributed ratings of hot flash and sleep, pain, mood, cognitive, and tension symptoms from the health diaries on at least one occasion between 1990 and 2011; were in late reproductive stage, early or late MT stage, or early PM during the course of the study and provided a first-morning urine sample on at least one occasion; and for whom assays of estrone, FSH, testosterone, cortisol, epinephrine, and norepinephrine were available. Women whose menstrual calendars were not assigned an MT stage because of hormone use were excluded. This sample provided data points for 3,175 measurement occasions.
Measures Symptoms
A 3-day health diary included 47 symptoms that were rated for severity over the previous 24 hours on a 5-point Likerttype scale (0, not present; 4, extreme). 16 Women completed the diary for three consecutive days each month through 2000 and completed the diary four times per year (quarterly) thereafter. Women filled out the diary on menstrual cycle days 5, 6, and 7 if they were still having periods; if not, they filled out the diary on any consistent 3 days each month or each quarter. Ratings were averaged across 3 days. 16 The five symptom groups used in these analyses were determined from a previous principal components analysis of the following 15 individual symptoms: early awakening, awakening at night, difficulty falling to sleep (sleep); joint pain, backache, headache (pain); depressed, mood changes, crying, irritable (mood); problem concentrating, forgetful (cognitive); nervous, panic, tension (tension). 31 Hot flash was used as a single symptom.
Biomarkers
All urinary assays were performed at the University of Washington Center for Women's Health Research laboratories using a first-voided morning urine specimen provided on day 6 of the menstrual cycle, if menstrual periods were identifiable. For women with no bleeding, spotting, or extremely erratic flow, a consistent date each month was used. Women abstained from smoking, caffeine, and exercise before urine collection. Urine samples were preserved with sodium ethylenediaminetetraacetic acid and sodium metabisulfite and frozen at j70-C. All specimens, standards, and controls were tested in duplicate, and those with a coefficient of variation higher than 15% were repeated. A BioRad Quantitative Urine control and a pooled in-house urine control were included in all assays, and a member of the standard curve was repeated after every 10 unknowns to monitor assay performance. In general, all samples from a calendar year were assayed during the next calendar year, and multiple samples from each participant were assayed in the same batch during each year. All endocrine concentrations were corrected for variations in urine concentration by expressing hormone level as a ratio to concentration in the same urine specimen. 32 The methods by which each of these biomarkers were assayed are described in greater detail elsewhere. 16 
HPO axis biomarkers Urinary estrone glucuronide
Urinary estrone glucuronide (E1G) was measured by a competitive enzyme immunoassay that cross-reacts 83% with estradiol glucuronide, thus measuring both estradiol and estrone in glucuronide forms. 33<35 As demonstrated in prior studies of the MT, 36 the E1G assay developed by O'Connor et al 37, 38 captures meaningful patterns of change with respect to reproductive aging. The assay is described in full elsewhere. 37 Measures of urinary E1G in our sample are expressed in nanograms per milligram of creatinine.
Urinary FSH
FSH was assayed using the Siemens Double-Antibody FSH radioimmunoassay kit. FSH levels assayed in urine were parallel with serum profiles obtained from reproductive-aged women during the menstrual cycle. In our laboratory, the reporting range for urine FSH is 2.0 to 100 mIU/mL, and the minimal detectable concentration is 1.6 mIU/mL. The interassay variation (run to run) was 7.1%, and the intra-assay variation (within run) was 3.7% (n = 205).
Urinary testosterone
Testosterone levels were assayed using the Siemens Total Testosterone Kit, a solid-phase radioimmunoassay with a testosterone-specific antibody immobilized to the wall of a polypropylene tube. Standards ranging from 25 to 400 ng/dL were used. The mean recovery was 92.7% and ranged from 86.1% to 106%. The interassay variation was 12.38% (n = 791), and the intra-assay variation (within run) was 8.75%. Testosterone levels used in the analysis were reported as nanograms of testosterone per milligram of creatinine.
Urinary cortisol
Urine cortisol levels were determined by radioimmunoassay using Coat-A-Count Cortisol Kit (Siemens Medical Solutions, Los Angeles, CA). The Coat-A-Count Cortisol Kit is designed for the quantitative measurement of unbound cortisol (hydrocortisone, compound F) in serum, urine, and heparinized plasma. The assay is highly specific for cortisol and has extremely low cross-reactivity with other steroids, except for prednisolone. 39, 40 All participants using prednisone or prednisolone were excluded from analysis.
In our laboratory, the reporting range for this urinary cortisol assay is 1 to 50 Kg/dL, and the minimal detectable concentration is 0.2 Kg/dL. Interassay precision was calculated for each of the three samples from the results of 20 extractions each. The coefficients of variation (interassay) ranged from 8.2% to 12.5% for samples ranging from 0.9 to 8.3 Kg/dL. The intra-assay coefficient of variation was 4.6% (n = 376) using a pooled in-house control (3.6 Kg/dL).
Urinary epinephrine and norepinephrine
We assayed epinephrine and norepinephrine by highperformance liquid chromatography after extraction on Bio-Rex cation exchange resin (Bio-Rad, Redmond, WA), followed by aluminum oxide (Bio-Rad) precipitation, using a modification of liquid chromatography and electrochemical (detection) application note no. 15 (Bioanalytical Systems, 1982) . The intra-assay variation is 4.7%, and the interassay variation is 7.85%.
MT stages and early PM
MT refers to the period leading up to the final menstrual period in which persistent menstrual irregularity occurs. 41 With the use of menstrual calendar data, menstrual patterns for women not taking any hormones were classified according to the stages of reproductive aging (late reproductive, early MT, or late MT) based on the staging criteria developed by Mitchell et al 42 and validated in later studies. 43<45 Early PM includes the 5 years after the final menstrual period. The names of stages and the definition of early PM match those recommended at the Stages of Reproductive Aging Workshop 41 and validated in follow-up studies by ReSTAGE Collaboration. 42 The Stages of Reproductive Aging Workshop criteria define the stages as follows: early transition is characterized by the persistence of a 7-day or longer difference between two consecutive cycle lengths; late transition is characterized by an amenorrhea interval of at least 60 days; and early PM is defined as the first 5 years since the final menstrual period. 43<45 The final menstrual period is defined as the last day of the final menses, using data for at least 1 year after this event.
Data analysis
Multilevel latent class analysis was used to identify empirically latent classes of menopausal symptoms based on individual diary observations, using the five symptom groups identified from a previous principal components analysis and using hot flash as an individual symptom. Traditional latent class analysis is a statistical method used to identify subgroups of related cases that are not directly observed based on categorical or continuous observed variables. This traditional method assumes independence, whereas multilevel latent class analysis allows for the nested structure of diary data. 46<50 All models use monthly symptom episodes as the unit of measure and account for the clustering of symptom episodes within individual women. The HPO axis (E1G, FSH, and testosterone), HPA axis (cortisol), and ANS (epinephrine and norepinephrine) biomarkers were included as covariates to assess effects on class membership. Table 1 , women whose data were available for analysis and who were eligible for inclusion were midlife women with a mean (SD) age of 48.5 (4.0) years and a mean (SD) length of education of 16.1 (2.5) years at the beginning of the study. Most women (98.5%) were employed; 76% were married or partnered; 22% were divorced, separated, or widowed; and 2% were never married or partnered. Eligible women described themselves as African American (5.4%), Asian/Pacific Islander (7.7%), or white (86.9%). As seen in Table 1 , the women who were included in this analysis, compared with those who were ineligible, were slightly older and less likely to be a smoker but were similar in employment status, ethnicity, marital status, education, body mass index, and exercise activity level.
RESULTS
As seen in
As in prior analyses, we found three classes of symptom severity cluster episodes: high-severity hot flash, low hot flash, and all low symptoms. Class 1 accounted for 13% of the sample and included high-severity hot flash and lower severity levels of other symptoms. Class 2 accounted for 17% of the sample and included low-severity hot flashes and moderateseverity levels of other symptoms. Class 3 accounted for 70% of the sample and included low-severity symptoms.
As seen in Table 2 , relative to the low-severity symptom class (class 3), higher levels of estrogen (odds ratio [OR], 0.016) significantly reduced the likelihood of being in the high hot flash class (class 1), whereas women with higher levels of FSH (OR, 2.870) were significantly more likely to be in the high hot flash class. Higher levels of epinephrine reduced the likelihood of being in the high hot flash class (OR, G0.001), and higher levels or norepinephrine increased the likelihood of being in this class relative to the low-severity symptom class (OR, 10.507). There were no significant effects found for cortisol or testosterone levels.
In addition, epinephrine levels significantly differentiated the low hot flash/moderate-severity symptom cluster (class 2) from the low-severity symptom cluster (class 3; OR, 0.001). Having lower epinephrine levels increased the likelihood of having the low hot flash/moderate-severity symptom cluster than the low-severity symptom cluster. None of the HPO axis biomarkers was associated with the low hot flash/moderateseverity symptom cluster, nor was cortisol or norepinephrine.
DISCUSSION
The analyses reported here assessed the direct effects of HPO axis (estrogen, FSH, and testosterone), HPA axis (cortisol), and ANS biomarkers (epinephrine and norepinephrine) on symptom severity clusters (latent classes). As we anticipated, the HPO axis biomarkers, estrogen and FSH, had a significant effect on symptom severity cluster membership, with lower levels of estrogen and higher levels of FSH increasing the probability of membership in the high-severity hot flash cluster as compared with the all-low symptom severity cluster. Testosterone and cortisol levels were not significantly related to cluster membership. Higher levels of the ANS biomarkers, epinephrine and norepinephrine, also had a significant effect on symptom severity cluster membership, with higher levels of epinephrine reducing the likelihood of belonging to the high hot flash cluster and with higher levels of norepinephrine conversely increasing the probability. Moreover, epinephrine was the sole biomarker for distinguishing membership in the low hot flash/moderateseverity symptom cluster from membership in the low symptom severity cluster.
These findings represent the first reports of both HPO axis and HPA axis/ANS biomarkers as correlates of symptom severity clusters that women experience during the late reproductive stage through the early PM stages of reproductive aging. Our earlier analyses indicated that the clusters of highseverity hot flashes with moderate levels of mood, sleep, cognitive, and pain symptoms were more likely to occur during the early and late MT stages and early PM. 8 Thus, it is not surprising that this cluster was associated with lower urinary estrone levels and high FSH levels given the trajectory of these endocrine changes during the MT and early PM. 9 Moreover, the association of hot flashes with sleep, mood, and pain symptoms, and with estrogen levels has been established in studies of individual symptoms. 4,9<16 The role of cortisol in the high hot flash/moderate-severity symptom cluster is puzzling. Analyses of individual symptoms in the SMWHS population have not linked cortisol to individual symptoms, including hot flashes and depressed mood, cognitive, pain, and sleep symptoms, 10, 16, 20, 22, 51 despite the observed rise in cortisol during the late MT stage. The association of cortisol with urinary estrone, FSH, and testosterone in the SMWHS population may suggest that the transition of estrogen production from an ovarian source to an adrenal source during the MT may be marked by a transient period in which levels of both cortisol and HPO axis hormones are elevated. 25 Nonetheless, cortisol does not seem to be associated with any of the symptom clusters in these analyses.
Earlier research focusing on hot flashes have established the relationship between norepinephrine levels and hot flashes, but these investigations did not include other symptoms in their reported analyses. 26, 27 Nonetheless, laboratory investigations have established the link between elevated norepinephrine levels and hot flashes. 26, 27 The associations of the ANS biomarkers with the low hot flash/moderate sleep, mood, cognitive, and pain symptom severity cluster are of interest. This symptom severity cluster was significantly associated with lower epinephrine levels, but not with norepinephrine or cortisol. Clustering of the sleep, mood, cognitive, and pain symptoms resembles the collection of emotional and somatic symptoms that are often included in measures of depressed mood symptoms. This cluster was not associated with the MT stages and early PM in our earlier analyses, nor was it significantly associated with the HPO axis biomarkers, suggesting that it may be associated with other factors such as the stressful nature of women's lives or their responses to aging. These explanations require further investigation.
Recent studies of stress reactivity in women revealed that hypoactive responses to stress were associated with depression 5 years later. 52 Chronic and repeated stressors may lead to persistent dysregulation of stress responsive systems, which has been characterized as allostatic load. 53 Exhaustion of stress responsive systems as a consequence of increased allostatic load may manifest in blunted sympathetic nervous system reactivity. Thus, dysregulation in stress responsive systems after repeated elevations of stress-related neuroendocrine responses may manifest in the current findings as lower epinephrine levels. Women with a history of abuse exhibit alterations in biological profiles modulated by their menstrual cycles. 54 Given that both estrogen and progesterone modulate A adrenergic responses, further research investigating the relationship between the MT and early PM, HPO axis endocrine changes, and symptoms such as those included in the cluster, with moderate levels of all but hot flashes, may contribute to understanding the abovedescribed relationship between this cluster and stress response.
The current report includes data from a subset of the SMWHS participants and thus is limited to generalizability to a well-educated and predominantly white population. These findings bear replication among a more ethnically diverse population such as those enrolled in the SWAN or the Penn Ovarian Aging.
CONCLUSIONS
Levels of urinary estrone, FSH, epinephrine, and norepinephrine differentiate women experiencing a symptom cluster with high-severity hot flashes and moderate levels of mood, sleep, cognitive, and pain symptoms from women with lowseverity symptoms. Having a low level of epinephrine distinguishes women with low-severity hot flashes and moderate levels of the other symptoms from women with low-severity symptoms during the MT and early PM. Taken together, these findings suggest that both the HPO axis and ANS function may be influential in symptom clusters that women experience during the MT and early PM.
